{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:01:23Z","timestamp":1791820883392,"version":"4.3.4"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T00:00:00Z","timestamp":1608163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T00:00:00Z","timestamp":1608163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"SFJ Pharmaceuticals"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s40265-020-01441-6","type":"journal-article","created":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T10:03:54Z","timestamp":1608199434000},"page":"257-266","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":103,"title":["Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations"],"prefix":"10.1007","volume":"81","author":[{"given":"Tony S.","family":"Mok","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangdong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Hyeong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Niho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alka","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Rosell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Corral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rita","family":"Migliorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Pluzanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay","family":"Noonan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malaika","family":"Pastel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith D.","family":"Wilner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3611-0258","authenticated-orcid":false,"given":"Yi-Long","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,17]]},"reference":[{"issue":"25","key":"1441_CR1","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","volume":"362","author":"M Maemondo","year":"2010","unstructured":"Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380\u20138.","journal-title":"N Engl J Med"},{"issue":"3","key":"1441_CR2","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","volume":"13","author":"R Rosell","year":"2012","unstructured":"Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239\u201346.","journal-title":"Lancet Oncol."},{"issue":"9","key":"1441_CR3","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/annonc\/mdv270","volume":"26","author":"YL Wu","year":"2015","unstructured":"Wu YL, Zhou C, Liam CK, Wu G, Liu X, Zhong Z, et al. First-line erlotinib versus gemcitabine\/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label. ENSURE study. Ann Oncol. 2015;26(9):1883\u20139.","journal-title":"Ann Oncol."},{"issue":"9","key":"1441_CR4","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1093\/annonc\/mdv276","volume":"26","author":"C Zhou","year":"2015","unstructured":"Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Ann Oncol. 2015;26(9):1877\u201383.","journal-title":"Ann Oncol"},{"issue":"21","key":"1441_CR5","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1200\/JCO.2010.33.4235","volume":"29","author":"M Fukuoka","year":"2011","unstructured":"Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin\/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29(21):2866\u201374.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1441_CR6","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1093\/annonc\/mds214","volume":"24","author":"A Inoue","year":"2013","unstructured":"Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol. 2013;24(1):54\u20139.","journal-title":"Ann Oncol"},{"issue":"12","key":"1441_CR7","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1093\/annonc\/mdz399","volume":"30","author":"H Yoshioka","year":"2019","unstructured":"Yoshioka H, Shimokawa M, Seto T, Morita S, Yatabe Y, Okamoto I, et al. Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB\/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. Ann Oncol. 2019;30(12):1978\u201384.","journal-title":"Ann Oncol"},{"issue":"11","key":"1441_CR8","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","volume":"18","author":"YL Wu","year":"2017","unstructured":"Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(11):1454\u201366.","journal-title":"Lancet Oncol."},{"issue":"24","key":"1441_CR9","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.2217\/fon-2019-0299","volume":"15","author":"J Corral","year":"2019","unstructured":"Corral J, Mok TS, Nakagawa K, Rosell R, Lee KH, Migliorino MR, et al. Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer. Future Oncol. 2019;15(24):2795\u2013805.","journal-title":"Future Oncol."},{"issue":"22","key":"1441_CR10","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1200\/JCO.2018.78.7994","volume":"36","author":"TS Mok","year":"2018","unstructured":"Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, et al. Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations. J Clin Oncol. 2018;36(22):2244\u201350.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1441_CR11","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1200\/JCO.2013.53.8009","volume":"32","author":"LM Ellis","year":"2014","unstructured":"Ellis LM, Bernstein DS, Voest EE, Berlin JD, Sargent D, Cortazar P, et al. American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol. 2014;32(12):1277\u201380.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1441_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):41\u201350.","journal-title":"N Engl J Med"},{"issue":"2","key":"1441_CR13","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/annonc\/mdw611","volume":"28","author":"L Paz-Ares","year":"2017","unstructured":"Paz-Ares L, Tan EH, O\u2019Byrne K, Zhang L, Hirsh V, Boyer M, et al. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol. 2017;28(2):270\u20137.","journal-title":"Ann Oncol"},{"issue":"5","key":"1441_CR14","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","volume":"17","author":"K Park","year":"2016","unstructured":"Park K, Tan EH, O\u2019Byrne K, Zhang L, Boyer M, Mok T, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016;17(5):577\u201389.","journal-title":"Lancet Oncol."},{"issue":"13","key":"1441_CR15","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2217\/fon-2018-0944","volume":"15","author":"Q Zhou","year":"2019","unstructured":"Zhou Q, Wu YL, Corral J, Nakagawa K, Garon EB, Sbar EI, et al. Management of common adverse events related to first-line dacomitinib use in EGFR mutation-positive non-small-cell lung cancer: a pooled safety analysis. Future Oncol. 2019;15(13):1481\u201391.","journal-title":"Future Oncol."},{"key":"1441_CR16","doi-asserted-by":"crossref","unstructured":"Tan A, Mok T, Kim D, Yang JC, Lee C, Soo R, et al. ATORG-003: dacomitinib with or without dose titration as first-line therapy for metastatic EGFR mutant non-small cell lung cancer. J Thorac Oncol. 2019;14(10 (Supplement)):S836\u20137.","DOI":"10.1016\/j.jtho.2019.08.1805"},{"issue":"13","key":"1441_CR17","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/S1470-2045(14)70461-9","volume":"15","author":"PA Janne","year":"2014","unstructured":"Janne PA, Ou SI, Kim DW, Oxnard GR, Martins R, Kris MG, et al. Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2014;15(13):1433\u201341.","journal-title":"Lancet Oncol."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01441-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-020-01441-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01441-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T06:36:45Z","timestamp":1614839805000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-020-01441-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,17]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["1441"],"URL":"https:\/\/doi.org\/10.1007\/s40265-020-01441-6","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,17]]},"assertion":[{"value":"17 December 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was sponsored by Pfizer Inc and SFJ Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Tony Mok: grant\/research funding (paid to institution): AstraZeneca, Bristol-Myers Squibb, Clovis Oncology, G1 Therapeutics, Merck Sharp & Dohme, Merck Serono, Novartis, Pfizer, Roche, SFJ, Takeda, and XCovery; speaker\u2019s fees: ACEA Pharma, Alpha Biopharma Co., Ltd., Amgen, Amoy Diagnostics Co., LTD., AstraZeneca (before Jan 2019), Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, InMed Medical Communication, Merck Sharp & Dohme, Novartis, Pfizer, PrIME Oncology, Roche\/Genentech, Taiho, and Takeda Oncology; honoraria for consultation services: Abbvie Inc., ACEA Pharma (since Aug 2018), Alpha Biopharma Co., Ltd., Amgen, Amoy Diagnostics Co., Ltd., AstraZeneca (before Jan 2019), Bayer, Boehringer Ingelheim, Blueprint Medicines Corporation, Bristol-Myers Squibb, Celgene, CStone Pharmaceuticals, Daiichi Sankyo, Eli Lilly, Fishawack Facilitate Ltd., Hengrui Therapeutics Inc., Ignyta, Inc., Incyte Corporation, InMed Medical Communication, IQVIA, Janssen, Loxo-Oncology, Merck Serono, Merck Sharp & Dohme, MoreHealth, Novartis, OncoGenex Pharmaceuticals, Inc., OrigiMed, PeerVoice, Pfizer, PrIME Oncology, Roche\/Genentech, Sanofi-Aventis R&D, SFJ Pharmaceutical Ltd., Takeda Pharmaceuticals HK Ltd., Vertex Pharmaceuticals, Yuhan Corporation, Medscape\/WebMD (medical education\/CME activities), PeerVoice (independent medical education), Prime Oncology (medical education); stock shareholder\/option: Clearbridge Biomedics (now Biolidics Ltd.), Hutchison Chi-Med, Loxo-Oncology, OrigiMed Co. Ltd., Sanomics Ltd., and Virtus Medical Group; advisory board: Abbvie Inc., ACEA Pharma, Amgen, AstraZeneca, Bayer, Blueprint Medicines Corporation, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Cirina, CStone Pharmaceuticals, Daiichi Sankyo, Eli Lilly, Fishawack Facilitate Ltd., G1 Therapeutics, Inc., geneDecode Co., Ltd. (uncompensated), Hengrui Therapeutics Inc., Hutchison Chi-Med, Ignyta, Inc., Incyte Corporation, IQVIA, Janssen, Loxo-Oncology, Lunit, Inc., Merck Serono, Merck Sharp & Dohme, Novartis, OncoGenex Technologies Inc., OrigiMed, Pfizer, Roche\/Genentech, Sanofi-Aventis R&D, SFJ Pharmaceutical, Takeda Oncology, Vertex Pharmaceuticals, Virtus Medical Group, and Yuhan Corporation; board of directors\/leadership (remunerated): AstraZeneca and Hutchison Chi-Med; board of directors\/leadership (non-remunerated): American Society of Clinical Oncology (ASCO), Asian Thoracic Oncology Research Group (ATORG), Chinese Lung Cancer Research Foundation Limited (CLCRF), Chinese Society of Clinical Oncology (CSCO), Hong Kong Cancer Fund (HKCF), Hong Kong Cancer Therapy Society (HKCTS), International Association for the Study of Lung Cancer (IASLC; term ended Apr 2019), and St. Stephen\u2019s College & Prep. School. Kazuhiko Nakagawa: grants: MSD K.K., A2 Healthcare Corp., inVentiv Health Japan Astellas Pharm Inc., Daiichi Sankyo Co., Ltd., Novarits Pharma K.K., AbbVie Inc., Quintiles Inc., IQVIA Services JAPAN K.K., ICON Japan K.K., Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., EP-CRSU CO., LTD., GRITSONE ONCOLOGY.INC, Linical Co., Ltd., Eli Lilly Japan K.K., Eisai Co., Ltd., Bristol-Myers Squibb, Nippon Boehringer Ingelheim Co., Ltd., Taiho Pharmaceutical Co., Ltd., Pfizer Japan Onc., PAREXEL International Corp., SymBio Pharmaceuticals Limited, Ono Pharmacuetical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., EPS Corporation, Bayer Yakuhin Ltd., Syneos Health, EPS International Co., Ltd., Pfizer R&D Japan G.K., Otsuka Pharmaceutical Co., Ltd.; honoraria: AstraZeneca K.K., Nichi-Iko Pharmaceutical Co., Ltd., Astellas Pharma Inc., Takeda Pharmaceutical Co., Ltd., MSD K.K., Taiho Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb, Nippon Boehringer Ingelheim Co., Ltd., Eli Lilly Japan K.K., Novartis Pharma K.K., SymBio Pharmaceuticals Limited, Pfizer Japan Inc., Chugai Pharmaceutical Co., Ltd., Clinical Trial Co., Ltd., NANZANDO Co., Ltd., MEDICUS SHUPPAN Publishers Co., Ltd., YODOSHA CO., LTD., Care Net Inc., Nikkei Business Publications Inc., Reno Medical K.K., Daiichi Sankyo Co., Ltd., KYORIN Pharmaceutical Co., Ltd., Thermo Fisher Scientific K.K., Medical Review Co., Ltd., YOMIURI TELECASTING CORPORATION, Roche Diagnostics K.K., Nippon Kayaku Co., Ltd., Bayer Yakuhin Ltd., Merck Biopharma Co., Ltd., Medical Mobile Communications Co., Ltd., AbbVie Inc., 3H Clinical Trial Inc. Seiji Niho: grants: AstraZeneca, Pfizer, Merck Biopharma, Eli Lilly, MSD, and Chugai; honoraria: AstraZeneca, Pfizer, Eli Lilly, Chugai, Taiho, MSD, Bristol-Myers Squibb, Novartis, Boehringer Ingelheim, Taiho, Ono, and Shionogi. Alka Chawla: former employee of SFJ Pharmaceuticals. Jesus Corral: Education grants, provided consultation, attended advisory boards and\/or provided lectures for Pfizer, AstraZeneca, Roche, Eli Lilly, MSD, and Bristol-Myers Squibb. Adam Pluzanski: lecture fees and travel grants: Pfizer. Kay Noonan, Yiyun Tang, Malaika Pastel, and Keith Wilner: Pfizer employees and stockholders. Yi-Long Wu: grants (to institute): AstraZeneca, BMS, Boehringer Ingelheim, Pfizer, and Roche; honoraria: AstraZeneca, Boehringer Ingelheim, MSD, and Roche; lectures\/speakers bureaus: AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly, MSD, Pfizer, and Roche. Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Rafael Rosell, and Maria Rita Migliorino: no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with legal and regulatory requirements, the general principles in the International Ethical Guidelines for Biomedical Research Involving Human Subjects (Council for International Organizations of Medical Sciences 2002), and the Declaration of Helsinki (World Medical Association 1996 and 2008).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Upon request, and subject to certain criteria, conditions and exceptions (see\u00a0\n                      \n                      for more information), Pfizer will provide access to individual de-identified\u00a0participant data from Pfizer-sponsored global interventional clinical studies conducted for medicines, vaccines and medical devices (1) for indications that have been approved in the US and\/or EU or (2) in programs that have been terminated (i.e., development for all indications has been discontinued). Pfizer will also consider requests for the protocol, data dictionary, and statistical analysis plan. Data may be requested from Pfizer trials 24\u00a0months after study completion. The de-identified\u00a0participant data will be made available to researchers whose proposals meet the research criteria and other conditions, and for which an exception does not apply, via a secure portal. To gain access, data requestors must enter into a data access agreement with Pfizer.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}